Neena Patil compensation by year
Jazz Pharmaceuticals Summary Compensation Table · all 4 fiscal years held| Component | FY2019 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $166,731 | $673,945 | $665,769 | $715,481 |
| Bonus | $62,500 | $0 | $0 | $0 |
| Stock awards | $1,645,439 | $2,865,730 | $3,149,233 | $4,844,096 |
| Option awards | $1,228,737 | $0 | $0 | $0 |
| Non-equity incentive | $100,000 | $320,000 | $473,000 | $720,000 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $2,375 | $17,760 | $21,072 | $19,962 |
| Total | $3,205,781 | $3,877,435 | $4,309,074 | $6,299,539 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Jazz Pharmaceuticals plc DEF 14A filed June 8, 2026, accession 0001232524-26-000029, and prior-year filings.
How this page was built: the Jazz Pharmaceuticals plc filed document, accession 0001232524-26-000029. Every figure is read from that document and cited to the page and table it appears in. Filed June 8, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 25,036 | $4,256,120 | — |
| PSU | 24,696 | $4,198,320 | — |
| RSU | 12,518 | $2,128,060 | — |
| RSU | 9,261 | $1,574,370 | — |
| RSU | 8,852 | $1,504,840 | — |
| RSU | 5,778 | $982,260 | — |
| RSU | 4,709 | $800,530 | — |
| RSU | 2,221 | $377,570 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Jazz Pharmaceuticals plc's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2025 proxy (filed June 8, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-10 | Sale | 10b5-1 | 1,200 | $240.94 | 47,671 |
| 2026-06-30 | Tax withholding | — | 2,678 | $237.72 | 48,871 |
| 2026-06-10 | Sale | 10b5-1 | 1,200 | $231.83 | 51,549 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Jazz Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Renee Gala | President, CEO and Director | $19,151,558 |
| Bruce Cozadd | Chairperson and Former CEO | $18,834,836 |
| Robert Iannone | Executive Vice President, Global Head of Research and Development and Chief Medical Officer | $8,661,758 |
| Philip Johnson | Executive Vice President and CFO | $7,544,473 |
| Neena Patil · this page | Executive Vice President and Chief Legal Officer | $6,299,539 |
| Samantha Pearce | Executive Vice President, Chief Commercial Officer | $6,076,127 |
Neena Patil's compensation dossier, Jazz Pharmaceuticals
You have read Neena Patil's totals and holdings. The dossier adds each equity grant Jazz Pharmaceuticals disclosed for Neena Patil and Jazz Pharmaceuticals's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Jazz Pharmaceuticals compensation record
free company briefThis page is one person within Jazz Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Jazz Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Jazz Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Jazz Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.